Tests finerenone safety in children with kidney disease and protein in urine
Tests finerenone with an ACE inhibitor or ARB in children with kidney disease.
Key facts
- Who runs it
- Bayer
- Where
- Soweto, South AfricaSee the siteAlso in 31 other countries, 147 sites
- Registry title
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 100 people, planned
- Started
- 8 Nov 2022
- Expected to end
- 31 Aug 2028
- Type of study
- Interventional
- Treatments tested
- Finerenone (Kerendia, BAY94-8862)
- Record updated
- 24 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with chronic kidney disease and protein in the urine who took part in the earlier FIONA study and take an ACE inhibitor or ARB.
- Age
- From 1 year to 18 years.
- Sex
- All sexes can join.
- Disease stage
- Chronic kidney disease stages 1-3 (eGFR 30 mL/min/1.73m^2 or higher).
- Earlier treatment
- Must have taken part in the FIONA study (19920) and not permanently stopped treatment there. Must take an ACE inhibitor or ARB at the highest dose they can tolerate, unchanged for at least 30 days.
- Biomarker or test result
- Blood potassium of 5.0 mmol/L or lower for children 2 years and older, and 5.3 mmol/L or lower for children under 2 years.
Main reasons for not taking part
- Planned kidney transplant or planned urological surgery that may affect the kidneys
- Stage 2 high blood pressure, or low blood pressure
- Severe liver problems (for example Child-Pugh C)
- Taking an MRA, SGLT2 inhibitor, renin inhibitor, ARNI, potassium-sparing diuretic, or ACE inhibitor and ARB together
- Pregnant, breastfeeding, or planning to become pregnant during the study
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Participants must be ≥1 year to 18 years of age, at the time of signing the informed consent/assent
- Prior participation in the finerenone Phase 3 study FIONA (19920) and not permanently discontinued from treatment by the end of treatment (EoT) visit in FIONA
- Participants must have a clinical diagnosis of chronic kidney disease (CKD) at Visit 1 which is defined as; CKD stages 1-3 (estimated glomerular filtration rate [eGFR] ≥30 mL/min/1.73m\^2) for children ≥1 year to <19 years of age at FIONA EoT and at Visit 1
- Treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at optimized doses defined as maximally tolerable doses within the recommended dose range according to guidelines on blood pressure (BP) management, unchanged for at least 30 days prior to Visit 1
- K+ ≤5.0 mmol/L for children ≥2 years of age at both FIONA EoT and Visit 1, and ≤5.3 mmol/L for children <2 years of age at both FIONA EoT and Visit 1
- Participants who have reached legal age of consent: Capable of giving signed informed consent
- Participant is able to receive enteral feeding (solid food, bottle or cup fed, feeding through nasogastric or gastric feeding tubes) with or without breastfeeding
Who cannot take part
- Planned urological surgery expected to influence renal function
- Patients who are candidates for renal transplantation, i.e., a kidney transplantation scheduled within the study time frame
- Concomitant therapy with both ACEI and ARBs together
- Concomitant therapy with strong cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors, moderate or strong CYP3A4 inducers
- Previous assignment to treatment during this study
- Systemic hypertension Stage 2 defined according to institutional guidelines on BP management at Visit 1
- Known hypersensitivity to the study treatment (active substance or excipients)
- Severe hepatic insufficiency defined by e.g. Child-Pugh C or analogous scores
- Concomitant therapy with a mineralocorticoid receptor antagonist (MRA)(eplerenone, spironolactone, esaxerenone, canrenone), any renin inhibitor (aliskiren, enalkiren, remikiren), any sodium-glucose co-transporter-2 (SGLT2) inhibitor (SGLT2i), sacubitril/valsartan combination (ARNI), or potassium-sparing diuretic (amiloride, triamterene)
- Systemic hypotension defined as symptomatic hypotension or a mean systolic BP below the 5th percentile for age, sex and height but no lower than 80 mmHg for participants <18 years and symptomatic hypotension or a mean systolic blood pressure (SBP) <90 mmHg in participants ≥18 years at Visit 1
- Participants using rituximab, cyclophosphamide, abatacept, or intravenous glucocorticoids
- Simultaneous participation in another interventional clinical study (e.g., Phase 1 to 4 clinical studies)
- Any suspected (serious) adverse event related to study intervention which led to permanent discontinuation during the FIONA study
- Pregnant or breastfeeding or intention to become pregnant during the study
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 1 and 18 years old?
This trial is currently available in South Africa.
Also in 31 other countries, 147 sites
- Wits Vaccines & Infectious Diseases Analytics (VIDA) Research UnitSoweto, South AfricaTaking people
About the trial
What the trial wants to find out
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine.
Read full original descriptionShow less
The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known as hypertension. Vice versa, hypertension and proteinuria can also contribute to worsening of CKD. Therefore, the treatment of CKD aims to control blood pressure and proteinuria. There are treatments available for doctors to prescribe to children with CKD and hypertension and/or proteinuria. These include "angiotensin-converting enzyme inhibitors" (ACEI) and "angiotensin receptor blockers" (ARB). Both ACEI and ARB can help improve kidney function by reducing the activity of the renin-angiotensin-aldosterone system (RAAS). The RAAS is a system that works with the kidneys to control blood pressure and the balance of fluid and electrolytes in the blood. In people with CKD, the RAAS is often too active, which can impair the ability of the kidneys to work properly and cause hypertension and proteinuria. However, ACEI or ARB treatment alone does not work for all patients with CKD as they only target the angiotensin part of the renin-angiotensin-aldosterone system.
The study treatment, finerenone, is expected to help control RAAS overactivation together with an ACEI or ARB.
So, the researchers in this study want to learn more about whether finerenone given in addition to either an ACEI or ARB can help their kidney function.
The main purpose of this study is to learn how safe the treatment is when used of finerenone in addition to an ACEI or ARB in long-term.
To see how safe the treatment is, the study team will collect information on medical problems which are also known as "treatment emergent adverse events" (TEAEs). And they will also collect levels of an electrolyte called potassium in the blood by taking blood samples, and measure blood pressure during the study.
The secondary purpose of this study is to learn how well long-term use of finerenone can reduce the amount of protein in the participants' urine and benefit kidney function when taken with standard of care.
To see how the treatment works, the study team will collect participants' urine samples to assess urinary albumin-to-creatinine ratio (UACR) and urinary protein-to-creatinine ratio (UPCR), which are important assessments for calculating the level of protein in the urine. Researchers will also collect blood samples to analyze serum creatinine and calculate estimated glomerular filtration rate (eGFR). A significant decline in eGFR indicates worsening kidney function.
The study will include participants who had previously participated in FIONA study (NCT05196035). The participants will be aged from 1 year up to 18 years.
The participants will be in the study for approximately 19 months. They will take study treatment for up to 18 months and will be follow up for 1 month. During this period, at least 12 visits are planned for patients who newly start finerenone, and at least 8 visits for patients who already received finerenone.
In the visit, the study team will:
* have their blood pressure, heart rate, temperature, height and weight measured * have blood and urine samples taken * have physical examinations * have their heart examined by an electrocardiogram and echocardiography (a sonogram of the heart) * answer questions about their medication and whether they have any adverse events, or have their parents or guardian's answer * answer questions about how they are feeling, or have their parents or guardian's answer * answer question about how they like the study medication, or have their parents or guardian's answer The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
The doctors will check the participants' health about 30 days after the participants take their last treatment.
The group in the trial
- Finerenone Open-Label safety ExtensionTreatment being tested
Participants will receive finerenone treatment.
Treatment: Finerenone (Kerendia, BAY94-8862)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
- Plain-language title
- Tests finerenone safety in children with kidney disease and protein in urineGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT05457283, who can take part
- Record updated
- 24 September 2026